NO20070127L - Fremgangsmate for behandling av granuloma annulare eller sarkoid - Google Patents

Fremgangsmate for behandling av granuloma annulare eller sarkoid

Info

Publication number
NO20070127L
NO20070127L NO20070127A NO20070127A NO20070127L NO 20070127 L NO20070127 L NO 20070127L NO 20070127 A NO20070127 A NO 20070127A NO 20070127 A NO20070127 A NO 20070127A NO 20070127 L NO20070127 L NO 20070127L
Authority
NO
Norway
Prior art keywords
sarcoid
procedure
treatment
granuloma
annular
Prior art date
Application number
NO20070127A
Other languages
English (en)
Norwegian (no)
Inventor
Bernard S Goffe
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20070127L publication Critical patent/NO20070127L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20070127A 2004-06-09 2007-01-08 Fremgangsmate for behandling av granuloma annulare eller sarkoid NO20070127L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57876804P 2004-06-09 2004-06-09
US57909604P 2004-06-10 2004-06-10
PCT/US2005/020342 WO2005123777A2 (en) 2004-06-09 2005-06-08 Method of treating granuloma annulare or sarcoid

Publications (1)

Publication Number Publication Date
NO20070127L true NO20070127L (no) 2007-01-08

Family

ID=35355731

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070127A NO20070127L (no) 2004-06-09 2007-01-08 Fremgangsmate for behandling av granuloma annulare eller sarkoid

Country Status (11)

Country Link
US (1) US7396530B2 (es)
EP (1) EP1756163A2 (es)
JP (1) JP2008507592A (es)
AU (1) AU2005254980A1 (es)
BR (1) BRPI0511305A (es)
CA (1) CA2568570A1 (es)
IL (1) IL179557A0 (es)
MX (1) MXPA06014354A (es)
NO (1) NO20070127L (es)
RU (1) RU2006146939A (es)
WO (1) WO2005123777A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2383525T3 (es) 2003-11-05 2012-06-21 Sarcode Bioscience Inc. Moduladores de la adhesión celular
EP3797775A1 (en) 2007-10-19 2021-03-31 Novartis AG Compositions and methods for treatment of diabetic retinopathy
ES2763703T3 (es) * 2008-04-15 2020-05-29 Sarcode Bioscience Inc Antagonistas de LFA-1 tópicos utilizados en el tratamiento localizado de trastornos inmunes
EP2888283B1 (en) 2012-08-24 2018-09-19 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
RU2671516C1 (ru) * 2018-01-10 2018-11-01 Федеральное государственное бюджетное военное образовательное учреждение высшего образования Военно-медицинская академия имени С.М. Кирова Министерства обороны Российской Федерации (ВМедА) Способ лечения кольцевидной гранулемы

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002869A (en) * 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
US5071964A (en) * 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US5147637A (en) 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
NO900155L (no) 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
CA2008368C (en) 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
CA2011633C (en) 1989-03-09 2007-05-15 Timothy A. Springer Intercellular adhesion molecule - 2 and its binding ligands
CA2050329A1 (en) 1989-03-09 1990-09-10 Timothy A. Springer Method of treating viral infections using lfa-1
WO1990013281A2 (en) 1989-04-28 1990-11-15 Baylor College Of Medicine Method of suppressing hiv infection
EP0432249B1 (en) 1989-06-02 1996-09-25 The Johns Hopkins University School Of Medicine Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore
US5324510A (en) * 1989-09-01 1994-06-28 Boehringer Ingelheim Pharmaceuticals, Inc. Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
GB9009549D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
WO1991018011A1 (en) 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
AU667487B2 (en) 1991-10-01 1996-03-28 General Hospital Corporation, The Preventing allograft rejection with antibodies to adhesion molecules
DE69229275T2 (de) * 1991-10-04 1999-12-30 Us Health Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
GB2266664A (en) 1992-04-28 1993-11-10 Pierre Francois Piguet Monoclonal antibodies for prophylaxis and treatment of pulmonary fibrosis
DE69315847T2 (de) * 1992-08-21 1998-06-25 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
WO1998023761A1 (en) * 1996-11-27 1998-06-04 Genentech, Inc. HUMANIZED ANTI-CD11a ANTIBODIES
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
FR2763072B1 (fr) 1997-05-12 1999-11-05 Pasteur Merieux Serums Vacc Utilisation d'un anticorps monoclonal anti-lfa1 en transplantation renale
CO5140104A1 (es) * 1999-02-16 2002-03-22 Novartis Ag Derivados de mevinolina y preparacion farmaceuticas que los contienen
AR030817A1 (es) * 2000-10-02 2003-09-03 Novartis Ag Derivados de diazacicloalcanodiona

Also Published As

Publication number Publication date
JP2008507592A (ja) 2008-03-13
CA2568570A1 (en) 2005-12-29
EP1756163A2 (en) 2007-02-28
IL179557A0 (en) 2007-05-15
WO2005123777A2 (en) 2005-12-29
BRPI0511305A (pt) 2007-12-04
WO2005123777A3 (en) 2006-03-02
RU2006146939A (ru) 2008-07-20
AU2005254980A1 (en) 2005-12-29
US7396530B2 (en) 2008-07-08
MXPA06014354A (es) 2007-02-19
US20060013818A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
NO20070127L (no) Fremgangsmate for behandling av granuloma annulare eller sarkoid
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
BR0314760A (pt) Compostos orgânicos
BRPI0510274A (pt) epìtopos relacionados à doença celìaca
NO20074509L (no) Kombinasjon av organiske forbindelser
NO20070906L (no) Fremgangsmate for behandling av hyperfosfatanemi ved anvendelse av lantanhydroksykarbonat
BRPI0416628A (pt) uso de compostos orgánicos
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2008050329A3 (en) Novel sirnas and methods of use thereof
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
NO20061818L (no) Fremgangsmate for a inhibere remnant lipoproteinproduksjon
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
NO20091296L (no) Fremgangsmate for behandling av slag med trombolytisk middel
NO20083836L (no) N-hydroksyakrylamidforbindelser
MX2008013827A (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual.
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
WO2007019153A3 (en) Methods for treating hypertension
NO20076245L (no) Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner
NO20070061L (no) 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
MA56187B1 (fr) Traitements de l'angio-oedème héréditaire
BRPI0518690A2 (pt) tratamento de doenÇa inflamatària do intestino
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
EA200970436A1 (ru) Соединения карбамата для лечения депрессии

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application